Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards ...

Jefferies analyst Andrew Tsai has maintained their bullish stance on SRPT stock, giving a Buy rating on December 19.Don't Miss Our New Year's ...

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2024 (the “Grant Date”) that were previously ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2024 (the “Grant ...

Japanese drugmaker Nippon Shinyaku infringed a Sarepta patent related to its Duchenne muscular dystrophy (DMD) drug Vyondys 53 and must pay $115.2 million in damages, a Delaware jury said on Friday.

LX-2006 is under development for the treatment of cardiomyopathy associated with Friedreich’s Ataxia. The drug candidate consists of Adeno-associated virus (AAV) vector carrying frataxin gene and is ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2024 (the “Grant Date”) that were ...

In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other gene therapy stocks. Gene therapy is referred to as a medical technique that ...